Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAMPKIN: Fampridine in Multiple Sclerosis gait analysis
NCT01576354Phase 2Unknown
- Sponsor
- University of Zurich
- Start
- Mar 2012
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dalfampridine in multiple sclerosis (MS), sponsored by University of Zurich. Primary endpoint: Walking pattern on treadmill at Week 6. Status: unknown.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01576354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01576354.